It is unfortunate that the data cutoff date was 10 March, so we are missing a month, but even so the BORR for the KEYNOTE study seems to be 13/41 or 32% and Disease control of 24/41 58%.
It appears at mo that CAVATAK may more suited to the Yervoy trial than Keytruda, though they are different types of trial.
It is unfortunate that the data cutoff date was 10 March, so we...
Add to My Watchlist
What is My Watchlist?